Do Institutional Investors Love Immunogen Inc (NASDAQ:IMGN)?

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Sentiment for Immunogen Inc (NASDAQ:IMGN)

Immunogen Inc (NASDAQ:IMGN) institutional sentiment increased to 1.29 in 2019 Q1. Its up 0.22, from 1.07 in 2018Q4. The ratio is positive, as 81 active investment managers opened new and increased equity positions, while 63 decreased and sold equity positions in Immunogen Inc. The active investment managers in our partner’s database now possess: 113.69 million shares, down from 119.32 million shares in 2018Q4. Also, the number of active investment managers holding Immunogen Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 22 Reduced: 41 Increased: 50 New Position: 31.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $412.18 million. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

The stock decreased 2.83% or $0.08 during the last trading session, reaching $2.75. About 1.10M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 76.42% since August 15, 2018 and is downtrending. It has underperformed by 76.42% the S&P500.

Redmile Group Llc holds 1.04% of its portfolio in ImmunoGen, Inc. for 13.06 million shares. Qvt Financial Lp owns 1.38 million shares or 0.87% of their US portfolio. Moreover, Fernwood Investment Management Llc has 0.27% invested in the company for 187,000 shares. The California-based Endurant Capital Management Lp has invested 0.2% in the stock. Birchview Capital Lp, a Vermont-based fund reported 90,000 shares.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Ratings analysis reveals 50% of ImmunoGen’s analysts are positive. Out of 6 Wall Street analysts rating ImmunoGen, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2.5 while the high is $12. The stock’s average target of $5.08 is 84.73% above today’s ($2.75) share price. IMGN was included in 13 notes of analysts from March 1, 2019. The firm earned “Buy” rating on Monday, March 4 by RBC Capital Markets. The stock has “Hold” rating by Jefferies on Friday, March 1. Piper Jaffray downgraded ImmunoGen, Inc. (NASDAQ:IMGN) rating on Friday, March 1. Piper Jaffray has “Hold” rating and $2.5 target. The firm earned “Buy” rating on Friday, March 1 by Canaccord Genuity. The stock has “Neutral” rating by H.C. Wainwright on Monday, March 4. Guggenheim maintained the shares of IMGN in report on Friday, March 1 with “Buy” rating.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: which released: “Health Care Sector Update for 05/15/2019: IMGN, A, ACBI, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on May 15, 2019, also with their article: “Notable Wednesday Option Activity: IMGN, FSLR, APC – Nasdaq” published on May 01, 2019, published: “Health Care Sector Update for 08/02/2019: APHA, TNDM, IMGN, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on August 02, 2019. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: and their article: “ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects? – Yahoo Finance” published on May 02, 2019 as well as‘s news article titled: “ImmunoGen’s mirvetuximab soravtansine flunks late-stage study; shares down 43% premarket – Seeking Alpha” with publication date: March 01, 2019.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.